Skip to main content
Atrás
RADLY logo

Raia Drogasil S.A.

Calidad de datos: 100%
RADLY
OTC Healthcare Medical - Pharmaceuticals
$4.80
▲ $0.26 (5.73%)
Cap. Mercado: 8.39B
Rango del Día
$4.52 $4.80
Rango de 52 Semanas
$2.21 $5.34
Volumen
2,100
Promedio 50D / 200D
$4.77 / $3.81
Cierre Anterior
$4.54

Quick Summary

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E 6.6 0.3
P/B 1.2 3.0
ROE % 18.5 3.7
Net Margin % 2.9 3.8
Rev Growth 5Y % 15.8 10.0
D/E 1.2 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2029 $1.82
$1.74 – $1.90
 72.49B 1
FY2028 $1.54
$1.48 – $1.61
 64.10B 1
FY2027 $1.27
$1.21 – $1.32
 57.14B 1

Dividend History

Yield

0.02%

Payout Ratio

N/A

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Puntos Clave

Revenue grew 15.80% annually over 5 years — strong growth
ROE of 18.50% — decent returns on equity
Generating 1.01B in free cash flow
P/E of 6.60 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4.18%
Capital efficient — spends only 3.17% of revenue on capex

Crecimiento

Revenue Growth (5Y)
15.80%
Revenue (1Y)11.62%
Earnings (1Y)6.15%
FCF Growth (3Y)N/A

Calidad

Return on Equity
18.50%
ROIC12.01%
Net Margin2.93%
Op. Margin5.96%

Seguridad

Debt / Equity
1.21
Current Ratio1.46
Interest Coverage2.46

Valoración

P/E Ratio
6.60
Forward P/EN/A
P/B Ratio1.15
EV/EBITDA6.46
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 11.62% Revenue Growth (3Y) 13.00%
Earnings Growth (1Y) 6.15% Earnings Growth (3Y) 9.78%
Revenue Growth (5Y) 15.80% Earnings Growth (5Y) 14.03%
Profitability
Revenue (TTM) 43.38B Net Income (TTM) 1.27B
ROE 18.50% ROA 4.99%
Gross Margin 24.75% Operating Margin 5.96%
Net Margin 2.93% Free Cash Flow (TTM) 1.01B
ROIC 12.01% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.21 Current Ratio 1.46
Interest Coverage 2.46
Dividends
Dividend Yield 0.02% Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 6.60 Forward P/E N/A
P/B Ratio 1.15 P/S Ratio 0.19
PEG Ratio 6.02 Forward PEG N/A
EV/EBITDA 6.46 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 12.01%
Market Cap 8.39B Enterprise Value 16.71B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 43.38B 38.86B 33.97B 29.07B 24.13B
Net Income 1.27B 1.20B 1.05B 996.11M 751.93M
EPS (Diluted) 0.77 0.72 0.62 0.58 0.44
Gross Profit 10.74B 11.55B 10.21B 8.81B 7.21B
Operating Income 2.59B 2.37B 2.08B 1.48B 1.22B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 25.46B 22.14B 20.09B 17.19B 14.78B
Total Liabilities 18.13B 15.70B 14.07B 11.78B 10.06B
Shareholders' Equity 7.32B 6.43B 5.96B 5.34B 4.68B
Total Debt 8.83B 7.70B 7.07B 6.06B 5.18B
Cash & Equivalents 509.36M 528.00M 412.32M 433.54M 356.12M
Current Assets 14.90B 12.70B 11.56B 9.58B 7.72B
Current Liabilities 10.19B 9.22B 8.08B 6.37B 5.90B

Puntuaciones de Estrategias

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#396 of 618
25
Custom Contrarian Investing (David Dreman)
#156 of 670
49

Actividad Reciente

Entró Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entró Contrarian Investing (David Dreman)
Mar 24, 2026